Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Our rating: False. There are no credible reports that Moderna "admitted" mRNA vaccines cause cancer, as the post claims. There is also no evidence that COVID-19 mRNA vaccines cause cancer.

Recently, Moderna released more phase III data on their RSV mRNA vaccine, and the vaccine saw a 25% decline in efficacy after 8.6 months, while GSK's subunit RSV vaccine Arexvy saw a 7% decline ...

Moderna’s mRNA vaccine candidate will target HSV-2, with the company indicating it expects immunity against that type of herpes should be somewhat cross-protective against HSV-1.

Moderna’s mRNA vaccine reaches its final phase. Here's how it works. The biotech firm's leading candidate has just entered phase three clinical trials in the U.S. Find out why this vaccine ...